# The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy

> **NCT00732654** · PHASE1,PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 30 (actual)

## Conditions studied

- Milk Allergy

## Interventions

- **DRUG:** Milk Protein Extract Immunotherapy goal of 4mg/day
- **DRUG:** Milk Protein Extract Immunotherapy goal of 7mg/day
- **DRUG:** Milk Powder Immunotherapy goal dose 2000 mg/day
- **DRUG:** Milk Powder Immunotherapy goal dose 1000mg/day

## Key facts

- **NCT ID:** NCT00732654
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-06
- **Final completion:** 2012-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00732654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00732654, "The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00732654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*